Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib with thalidomide and dexamethasone in relapsed/refractory multiple myeloma
2014-002749-23Phase 2Completed
- Sponsor
- AGMT
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in multiple myeloma (MM), sponsored by AGMT. Primary endpoint: progression-free survival. Started Dec 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-002749-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002749-23.